Novartis AG 2015 SR
The report highlights Novartis's 2015 sustainability progress, focusing on the launch of the Novartis Access portfolio to provide affordable treatments for noncommunicable diseases in low-income countries. The company achieved a 31% reduction in Scope 1 and 2 greenhouse gas emissions relative to its 2010 baseline, surpassing its 2020 target early. Key initiatives included reaching 66 million patients through access programs and delivering 300 million pediatric antimalarials without profit since 2009. Novartis also implemented a new ethics program and internal carbon pricing of USD 100 per ton to drive environmental investments.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2015
Type: SR
Pages: 91
Novartis AG
The report highlights Novartis's 2015 sustainability progress, focusing on the launch of the Novartis Access portfolio to provide affordable treatments for noncommunicable diseases in low-income countries. The company achieved a 31% reduction in Scope 1 and 2 greenhouse gas emissions relative to its 2010 baseline, surpassing its 2020 target early. Key initiatives included reaching 66 million patients through access programs and delivering 300 million pediatric antimalarials without profit since 2009. Novartis also implemented a new ethics program and internal carbon pricing of USD 100 per ton to drive environmental investments.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Published
Jan 26, 2016
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees